SENT FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy Development
Dear Colleague,
The emergency supply during a pandemic service, permissible
under Regulation 226 Human Medicines Regulations (HMRs) 2012, commenced on
Monday 6th April 2020 and operates during all the
pharmacy’s opening hours.
Emergency sale etc by pharmacist: pandemic diseases
HMR Reg 226.—(1) Regulation 214 (1) does not apply to the sale or supply of a
prescription only medicine by a person lawfully conducting a retail pharmacy
business if conditions A and B are met.
(2)
Condition A is that the supply is made whilst a disease is, or in anticipation
of a disease being imminently,—
(a) pandemic; and
(b) a serious risk, or potentially a serious risk, to human health.
(3)
Condition B is that the pharmacist by or under whose supervision the
prescription only medicine is to be sold or supplied is satisfied—
(a) that treatment with the prescription only medicine has on a previous occasion been prescribed by a relevant prescriber for the person to be treated with it; and
(b) as to the dose which in the circumstances it would be appropriate for that person to take.
It is for the responsible pharmacist to use their professional
judgement, based on the above regulations, to decide if and when a supply
should be made, the length of supply, and if it’s in the patient’s best
interests.
The
service aims to ensure that patients can access an urgent emergency supply
of their regular prescription medicines, where reasonable steps have been taken
but they are unable to obtain a prescription. As the most accessible healthcare
professionals, community pharmacists are ideally placed to help support
vulnerable patients
during this COVID pandemic. The service also
ensures equity of access to medicines irrespective of the patient’s ability to
pay, helping address health inequalities in the local community.
Contractors
should be aware that the emergency supply provisions previously available under
Regulations 224 and 225 are still in place and, where supply under 226 (outlined above)
is not applicable, consideration may be given to using 224 or 225 (remembering
the associated requirements on supply and on record keeping).
When can a supply be
made?
If a patient/representative
presents at the pharmacy, requesting an urgent supply of their regular
medication which they are short of, after reasonable steps had been taken
to obtain a prescription, a supply through the service can be made. There
may be instances where there has been a delay in the GP surgery printing
the prescription or during collection by the pharmacy.
It is vital your patients, especially
those who should not miss doses of medicines, such as patients with epilepsy,
continue to receive a supply of their medicines and the emergency supply during
a pandemic service is available to support that.
As with all new services there may be
some operational issues and we are aware that some GP practice staff are
querying some instances of when medicines were provided to patients under ESS.
If you are having issues with individual GP practices, in relation to the
service, please contact your local HSCB office to discuss. Similarly, if you
have any further queries about the service or are unsure about when the ESS can
be used please do not hesitate to contact Kerry Grimes kgrimes@communitypharmacyni.co.uk.
Feedback
The service is a great opportunity to
demonstrate how community pharmacists have the clinical expertise and are best
placed to support patients, especially those most vulnerable, in a professional
manner. To illustrate its value and the positive impact on the patient and the
wider health service, we are keen to gather community pharmacy case studies,
particularly again in respect of those in vulnerable groups.
When a patient has received their
medication through the service, it would be helpful to get some patient
feedback. What did they think of the service? Did they find it
efficient/useful? Would they wish to see the service continue? To demonstrate
its value, the pharmacist could encourage the patient to let a local MP/MLA
know how beneficial it was, particularly during this time of crisis.
This feedback and information gathering
is vital to help support CPNI in future service development.
If a patient has accessed the service
and would be interested in talking about their experience, please get in touch
with Jude Austin – judea@communitypharmacyni.co.uk or call the CPNI office on 028 9069 0444.
Yours sincerely
SENT FOR AND BEHALF
OF GERARD GREENE | Chief Executive
Dear Colleague
INVITATION TO COVID-19 HSCB ECHO
SESSION
Please find attached invitation
and agenda for an ECHO session being held this evening, Tuesday 28th April
2020, from 7.30pm to 9pm.
Links to register and access the
meeting are given in the invitation, please note the meeting may be accessed
via Zoom software.
Kind regards,
SENT FOR AND BEHALF OF GERARD GREENE |
Chief Executive
Download
Dear Colleague,
Further concessionary prices have been granted for April 2020:
Drug
Pack Size
Concessionary Price
Aciclovir
400mg tablets
56
£3.32
Co-codamol
15mg/500mg tablets
100
£3.99
Frovatriptan
2.5mg tablets
6
£11.91
Ibuprofen
400mg tablets
24
£2.00
Ibuprofen
400mg tablets
84
£6.99
Mometasone
50micrograms/dose nasal spray
140 dose
£5.95
Paracetamol
250mg/5ml oral suspension sugar free
200ml
£4.27
Sertraline
100mg tablets
28
£14.07
Sertraline
50mg tablets
28
£8.95
Sulpiride
200mg tablets
30
£6.86
Tacrolimus
0.1% ointment
30g
£25.92
Valaciclovir
500mg tablets
10
£20.59
Tamoxifen
20mg tablets
30
£5.50
Kind regards,
Katherine
SENT FOR AND BEHALF OF KATHERINE KIDD | Head of Pharmacy
Development
Dear Colleague,
Please find attached HSCB correspondence, relating to ongoing
supply of medicines to patients in instalments and in compliance aids, during
the COVID-19 pandemic.
Yours sincerely
SENT
FOR AND BEHALF OF GERARD GREENE | Chief Executive
Download
— UPDATE —
Dear Colleague,
New link for CPNI COVID Update #73
Please find attached a copy of the
letter that has been issued by HSCB regarding community pharmacy intentions for
opening on the May bank holiday.
The link for the survey has been updated. The new link is as follows:
SENT FOR AND BEHALF OF GERARD GREENE | Chief Executive
+++ Also see original CPNI COVID19 Update #73 +++
WhatsApp Business Terms of Service can be found here and privacy policy hereUCA-NI Privacy Policy We take your privacy seriously and do not share or sell any personal details with third parties for commercial purposes. If you have any questions, please contact the CPNI office. You can withdraw your consent to be contacted at any time by calling 028 9069 0444 or by emailing info@communitypharmacyni.co.uk. CPNI Data Protection Policy and Data Retention policy can be found Click Here
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.